RxDoctor Payments Data

Sylvia Parra, MD

Dermatology · Sumter, SCNPI 1245221712

Payments from drug & device makers

$726in general payments, 2019–2025

Across 39 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$232
  • Almirall LLC$178
  • Incyte Corporation$81
  • Novartis$44
  • AbbVie$41
  • Prugen, Inc. Pharmaceuticals$28
  • plus $122 from 7 others

What the payments were for

  • Food & beverage$726100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$726 in reported general payments places this provider in the 20th percentile of 203 dermatology providers in South Carolina.

See all dermatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$393,673
Medicare patients
1,309
Services billed
5,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab84$339,751
SkyriziRisankizumab-Rzaa12$236,354
Dupixent PenDupilumab18$86,257
Pimecrolimus13$3,164
Dutasteride35$2,955
Clobetasol Propionate69$2,623
Tacrolimus20$2,463
Triamcinolone Acetonide231$2,163
Fluorouracil32$2,130
Finasteride77$1,974
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc71$1,573
Ciclopirox12$1,560
Metronidazole33$1,518
Ketoconazole93$1,483
Hydroxychloroquine Sulfate21$1,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi$41$236,35412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 203 dermatology providers in South Carolina.

Other dermatology in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →